Advertisement

Journal of Parasitic Diseases

, Volume 42, Issue 3, pp 416–422 | Cite as

Preparation of meglumine antimonate loaded albumin nanoparticles and evaluation of its anti-leishmanial activity: an in vitro assay

  • Afshin Barazesh
  • Mohammad Hossein Motazedian
  • Naghmeh Sattarahmady
  • Mohammad Hossein Morowvat
  • Sajad Rashidi
Original Article
  • 26 Downloads

Abstract

Cutaneous leishmaniasis is still a health problem worldwide, especially in tropical and subtropical areas. Currently, pentavalent antimony compounds are used to treat leishmaniasis. These compounds cause various side effects in the body. Therefore, there is a need to discover new drugs with less toxicity and more therapeutic effects. In this study, we encapsulated the meglumine antimonate into the albumin as a drug carrier and evaluated the anti-leishmanial effect of the prepared nanoparticles. The precipitation method was used for this purpose by applying different concentrations of glutaraldehyde and N-(3-Dimethylaminopropyl)-N-ethyl carbodiimide hydro chloride Ethyl (DEC) and then, field emission test was performed using Scanning Electron Microscopy for evaluating the morphology and size particles. The cytotoxicity and inhibitory of drugs were evaluated on J774 macrophages and Leishmania major promastigotes, respectively. Nanodrugs prepared using glutaraldehyde (10 μl/ml) and DEC (13 mg/ml) had the smallest and largest size, respectively. The highest anti-leishmanial activity was observed in the drugs prepared with glutaraldehyde (10 μl/ml). Also this nanodrug had the lowest cytotoxicity against macrophages. Given that meglumine antimonate loaded albumin nanoparticles prepared with glutaraldehyde (10 μg/ml), can improve the anti-leishmanial effects of this old drug, it can be a good option as a drug delivery system.

Keywords

Meglumine antimonate Albumin Glutaraldehyde Encapsulation Anti-leishmanial activity 

Notes

Acknowledgements

This research is a part of the project approved by the Vice-Chancellor for Research of Shiraz University of Medical Sciences at Grant Number: 95-01-01-12795. Therefore, the authors express their gratitude and thanks to the approval and financial support of this plan.

Author contributions

Designed and performed the study: MHM; Nanoparticles syntesis: AB, NS, MHM; Performed the cell culture, anti-leishmanial assays and data analysis: AB, SR; Participated in writing the final paper: A B, MHM.

Compliance with ethical standards

Conflict of interest

Authors declare that they have no conflict of interest.

References

  1. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI (2002) Targeting to macrophages: role of physicochemical properties of particulate carriers—liposomes and microspheres—on the phagocytosis by macrophages. J Control Release 79:29–40CrossRefPubMedGoogle Scholar
  2. Benita S (2006) Microencapsulation methods and industrial applications. CRC Press, Boca RatonGoogle Scholar
  3. Borborema SE, Schwendener RA, Osso JA Jr, de Andrade HF Jr, do Nascimento N (2011) Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages. Int J Antimicrob Agents 38:341–347CrossRefPubMedGoogle Scholar
  4. Chowdhary SJ, Chowdhary A, Kashaw S (2016) Macrophage targeting: a strategy for leishmaniasis specific delivery. Int J Pharm Pharm Sci 8:16–26Google Scholar
  5. Dandagi PM, Mastiholimath VS, Patil MB, Gupta MK (2006) Biodegradable microparticulate system of captopril. Int J Pharm 307:83–88CrossRefPubMedGoogle Scholar
  6. Das S, Khan W, Mohsin Sh, Kumar N (2011) Miltefosine loaded albumin microparticles for treatment of visceral leishmaniasis: formulation development and in vitro evaluation. Polym Adv Technol 22:172–179CrossRefGoogle Scholar
  7. Date AA, Joshi MD, Patravale VB (2007) Parasitic diseases: liposomes and polymeric nanoparticles versus lipid nanoparticles. Adv Drug Deliv Rev 59:505–521CrossRefPubMedGoogle Scholar
  8. Desjeux P (1992) Human leishmaniases: epidemiology and public health aspects. World Health Stat Q 45:267–275PubMedGoogle Scholar
  9. Elzoghby AO, Samy WM, Elgindy NA (2012) Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 157:168–182CrossRefPubMedGoogle Scholar
  10. Fouladvand M, Barazesh A, Farokhzad F, Malekizadeh H, Sartavi K (2011) Evaluation of invitro anti-leishmanial activity of some brown, green and red algae from the Persian Gulf. Eur Rev Med Pharmacol Sci 15:597–600PubMedGoogle Scholar
  11. Fouladvand M, Barazesh A, Tahmasebi R (2013) Evaluation of in vitro antileishmanial activity of curcumin and its derivatives “gallium curcumin, Indium curcumin and diacetyle curcumin”. Eur Rev Med Pharmacol Sci 17:3306–3308PubMedGoogle Scholar
  12. Gour JK, Srivastava A, Kumar V, Bajpai S, Kumar H, Mishra M (2009) Nanomedicine and leishmaniasis: future prospects. Dig J Nanomater Biostruct 4:495–499Google Scholar
  13. Grinberg O, Hayun M, Sredni B, Gedanken A (2007) Characterization and activity of sonochemically-prepared BSA microspheres containing Taxol–an anticancer drug. Ultrason Sonochem 14:661–666CrossRefPubMedGoogle Scholar
  14. Gupta PK, Hung CT (1989) Albumin microspheres: applications in drug delivery. J Microencapsul 6:463–472CrossRefPubMedGoogle Scholar
  15. Jithan A, Madhavi K, Madhavi M, Prabhakar K (2011) Preparation and characterization of albumin nanoparticles encapsulating curcumin intended for the treatment of breast cancer. Int J Pharm Invest 1:119–125CrossRefGoogle Scholar
  16. Khan W, Kumar N (2011) Drug targeting to macrophages using paromomycin-loaded albumin microspheres for treatment of visceral leishmaniasis: an in vitro evaluation. J Drug Target 19:239–250CrossRefPubMedGoogle Scholar
  17. Kouchakzadeh H, Shojaosadati SA, Shokri F (2014) Efficient loading and entrapment of tamoxifen in human serum albumin based nanoparticulate delivery system by a modified desolvation technique. Chem Eng Res Des 92:1681–1692CrossRefGoogle Scholar
  18. Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132:171–183CrossRefPubMedGoogle Scholar
  19. Miele E, Spinelli GP, Miele E, Tomao F, Tomao S (2009) Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomedicine 4:99–105PubMedPubMedCentralGoogle Scholar
  20. Nejati J, Mojadam M, Hanafi Bojd AA, Keyhani A, Habibi Nodeh F (2014) An epidemiological study of cutaneous leishmaniasis in Andimeshk (2005–2010). SJIMU 21:94–101Google Scholar
  21. Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasseri K, Modabber F (2009) Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine 27:4747–4753CrossRefPubMedGoogle Scholar
  22. Paul M, Durand R, Boulard Y, Fusaï T, Fernandez C, Rivollet D, Deniau M, Astier A (1998) Physicochemical characteristics of pentamidine-loaded polymethacrylate nanoparticles: implication in the intracellular drug release in Leishmania major infected mice. J Drug Target 5:481–490CrossRefPubMedGoogle Scholar
  23. Peters T (1995) All about albumin. Biochemistry, genetics and medical applications. Academic press, San DiegoGoogle Scholar
  24. Reithinger R, Dujardin J, Louzir H, Pirmez C, Alexander B, Brooker S (2007) Cutaneous leishmaniasis. Lancet Infect Dis 7:581–596CrossRefPubMedGoogle Scholar
  25. Sabur A, Ali N (2015) Vaccine biology of Leishmania infection. In: Adak S, Datta R (eds) Leishmania, current biology and control. Caister Academic Press, Norfolk, pp 167–192CrossRefGoogle Scholar
  26. Sanchez-Brunete JA, Dea MA, Rama S, Bolas F, Alunda JM, Raposo R, Mendez MT, Torrado-Santiago S, Torrado JJ (2004) Treatment of experimental visceral leishmaniasis with amphotericin-B in stable albumin microspheres. Antimicrob Agents Chemother 48:3246–3252CrossRefPubMedPubMedCentralGoogle Scholar
  27. Sanchez-Brunete JA, Dea MA, Rama S, Bolas F, Alunda JM, Torrado-Santiago S, Torrado JJ (2005) Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin-B. J Drug Target 13:225–233CrossRefPubMedGoogle Scholar
  28. Santos DO, Coutinho CER, Madeira MF, Bottino CG, Vieira RT, Nascimento SB, Bernardino A, Bourguignon SC, Corte-Real S, Pinho RT, Rodrigues CR, Castro HC (2008) Leishmaniasis treatment—a challenge that remains: a review. Parasitol Res 103:1–10CrossRefPubMedGoogle Scholar
  29. Schafer V, von Briesen H, Rubsamen-Waigmann H, Steffan AM, Royer C, Kreuter J (1994) Phagocytosis and degradation of human serum albumin microspheres and nanoparticles in human macrophages. J Microencapsul 11:261–269CrossRefPubMedGoogle Scholar
  30. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A (2000) Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the indian epidemic. Clin Infect Dis 31:1104–1107CrossRefPubMedGoogle Scholar
  31. Veerareddy PR, Vobalaboina V, Nahid A (2004) Formulation and evaluation of oil-in-water emulsions of piperine in visceral leishmaniasis. Pharmazie 59:194–197PubMedGoogle Scholar
  32. Veerareddy PR, Vobalaboina V, Ali N (2009) Antileishmanial activity, pharmacokinetics and tissue distribution studies of mannosegrafted amphotericin-B lipid nanospheres. J Drug Target 17:140–147CrossRefPubMedGoogle Scholar
  33. Venier-Julienne MC, Vouldoukis I, Monjour L, Benoit JP (1995) In vitro study of the anti-leishmanial activity of biodegradable nanoparticles. J Drug Target 3:23–29CrossRefPubMedGoogle Scholar
  34. Wissing SA, Kayser O, Muller RH (2004) Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257–1272CrossRefPubMedGoogle Scholar
  35. World Health Organization (1995) WHO model prescribing information: drugs used in parasitic diseases, 2nd edn. World Health Organization, Geneva. http://www.who.int/iris/handle/10665/41765

Copyright information

© Indian Society for Parasitology 2018

Authors and Affiliations

  1. 1.Department of Parasitology and Mycology, School of MedicineShiraz University of Medical SciencesShirazIran
  2. 2.Nanomedicine and Nanobiology Research CenterShiraz University of Medical SciencesShirazIran
  3. 3.Department of Pharmaceutical Biotechnology, School of PharmacyShiraz University of Medical SciencesShirazIran
  4. 4.Department of Microbiology and Parasitology, Faculty of MedicineBushehr University of Medical SciencesBushehrIran

Personalised recommendations